Consolidated Financial Results

for the Three Months Ended April 30, 2022

[Japanese GAAP]

May 31, 2022

Company name: Tri Chemical Laboratories Inc.

Stock exchange listing: Tokyo Stock Exchange

Code number: 4369

URL: http://www.trichemical.com

Representative: Kiyoshi Tazuke, Representative Director & CEO

Contact: Yoshihide Suzuki, Executive Officer

Phone: +81-554-63-6600

Scheduled date of filing quarterly securities report: June 14, 2022

Scheduled date of commencing dividend payments: -

Availability of supplementary briefing material on quarterly financial results: Not available

Scheduled date of quarterly results briefing session: Not scheduled

(Amounts of less than one million yen are rounded down.)

1. Consolidated Financial Results for the Three Months Ended April 30, 2022 (February 1, 2022 to April 30, 2022)

(1) Consolidated Operating Results (cumulative)

(% indicates changes from the previous corresponding period.)

Net sales

Operating profit

Ordinary profit

Profit attributable to

owners of parent

Three months ended

Million yen

%

Million yen

%

Million yen

%

Million yen

%

April 30, 2022

3,119

20.2

986

36.5

1,718

39.2

1,293

37.0

April 30, 2021

2,594

13.4

723

1.4

1,234

12.3

944

9.2

(Note) Comprehensive income: Three Months ended April 30, 2022: ¥1,594 million (42.4%) Three Months ended April 30, 2021: ¥1,119 million (61.4%)

Basic earnings

Diluted earnings

per share

per share

Three months ended

Yen

Yen

April 30, 2022

39.80

-

April 30, 2021

29.36

-

(2) Consolidated Financial Position

Total assets

Net assets

Equity ratio

Million yen

Million yen

%

As of April 30, 2022

29,204

22,265

76.2

As of January 31, 2022

28,288

21,320

75.4

(Reference) Equity: As of April 30, 2022: ¥22,265 million As of January 31, 2022: ¥21,320 million

2. Dividends

Annual dividends

1st

2nd

3rd

Year-end

Total

quarter-end

quarter-end

quarter-end

Yen

Yen

Yen

Yen

Yen

Fiscal year ended January

-

0.00

-

20.00

20.00

31, 2022

Fiscal year ending January

-

31, 2023

Fiscal year ending January

0.00

-

22.00

22.00

31, 2023 (Forecast)

(Note) Revision of dividend forecasts from recently

announced figures: None

3. Consolidated Financial Results Forecast for the Fiscal Year Ending January 31, 2023 (February 1, 2022 to January 31, 2023)

(% indicates changes from the previous corresponding period.)

Net sales

Operating profit

Ordinary profit

Profit attributable

Basic earnings

to owners of parent

per share

Million yen

%

Million yen

%

Million yen

% Million yen

%

Yen

First half

6,590

22.8

1,690

15.9

2,590

5.8

2,010

6.8

61.85

Full year

13,600

17.5

3,400

14.2

5,730

8.2

4,500

9.9

138.47

(Note) Revision of financial results forecast from recently announced figures: None

* Notes:

  1. Changes in significant subsidiaries during the period under review: No (Changes in specific subsidiaries due to changes in the scope of consolidation)

New: - companies (company name)

, excluded: - companies (company name)

  1. Application of accounting treatment specific to preparation of quarterly consolidated financial statements: No
  2. Changes in accounting policies, changes in accounting estimates and retrospective restatement
    1. Changes in accounting policies due to the revision of accounting standards: Yes
    2. Changes in accounting policies other than 1) above: No
    3. Changes in accounting estimates: No
    4. Retrospective restatement: No
  4. Total number of issued shares (common shares)
    1. Total number of issued shares at the end of the period (including treasury shares):

As of April 30, 2022: 32,498,640 shares

As of January 31, 2022: 32,498,640 shares

  1. Total number of treasury shares at the end of the period: As of April 30, 2022: 1,580 shares
    As of January 31, 2022: 1,580 shares
  2. Average number of shares during the period:

Three months ended April 30, 2022: 32,497,060 shares

Three months ended April 30, 2021: 32,159,981 shares

  • These quarterly financial results are outside the scope of quarterly review by certified public accountants or an audit firm.
  • Explanation of the proper use of financial results forecast and other notes

The earnings forecasts and other forward-looking statements herein are based on information currently available to the Company and certain assumptions deemed reasonable, and do not represent a commitment by the Company that they will be achieved. Actual results may differ significantly from these forecasts due to a wide range of factors.

Quarterly Consolidated Financial Statements

(1) Quarterly Consolidated Balance Sheets

(Thousand yen)

As of January 31, 2022

As of April 30, 2022

Assets

Current assets

Cash and deposits

8,034,494

10,612,396

Notes and accounts receivable - trade

3,058,124

3,578,959

Electronically recorded monetary claims - operating

838,248

955,493

Merchandise and finished goods

79,197

103,293

Work in process

749,403

1,011,274

Raw materials and supplies

1,321,772

1,374,576

Other

305,191

211,058

Total current assets

14,386,432

17,847,053

Non-current assets

Property, plant and equipment

Buildings and structures

5,319,866

5,440,525

Accumulated depreciation

(1,500,630)

(1,579,353)

Buildings and structures, net

3,819,235

3,861,172

Machinery, equipment and vehicles

3,119,985

3,827,471

Accumulated depreciation

(1,708,130)

(1,798,420)

Machinery, equipment and vehicles, net

1,411,854

2,029,051

Tools, furniture and fixtures

2,616,297

2,698,628

Accumulated depreciation

(1,630,985)

(1,715,065)

Tools, furniture and fixtures, net

985,312

983,562

Land

714,933

714,933

Other

1,329,486

1,252,424

Accumulated depreciation

(246,748)

(269,910)

Other, net

1,082,737

982,514

Total property, plant and equipment

8,014,073

8,571,234

Intangible assets

181,431

166,631

Investments and other assets

Investment securities

5,535,422

2,336,514

Other

171,576

283,470

Total investments and other assets

5,706,999

2,619,985

Total non-current assets

13,902,504

11,357,852

Total assets

28,288,937

29,204,905

1

(Thousand yen)

As of January 31, 2022

As of April 30, 2022

Liabilities

Current liabilities

Accounts payable - trade

613,784

692,644

Current portion of long-term loans payable

961,417

917,223

Income taxes payable

800,361

504,675

Provision for bonuses

113,242

242,896

Other

976,639

1,434,153

Total current liabilities

3,465,445

3,791,593

Non-current liabilities

Long-term loans payable

2,699,229

2,502,381

Net defined benefit liability

118,662

121,331

Other

685,200

524,406

Total non-current liabilities

3,503,092

3,148,118

Total liabilities

6,968,537

6,939,712

Net assets

Shareholders' equity

Capital stock

3,278,912

3,278,912

Capital surplus

3,179,912

3,179,912

Retained earnings

14,626,625

15,270,172

Treasury shares

(1,720)

(1,720)

Total shareholders' equity

21,083,730

21,727,277

Accumulated other comprehensive income

Valuation difference on available-for-sale securities

1,473

2,153

Foreign currency translation adjustments

254,279

553,944

Remeasurements of defined benefit plans

(19,083)

(18,182)

Total accumulated other comprehensive income

236,669

537,915

Total net assets

21,320,399

22,265,193

Total liabilities and net assets

28,288,937

29,204,905

2

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Tri Chemical Laboratories Inc. published this content on 08 June 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 08 June 2022 06:11:07 UTC.